文献速递肾小球疾病

肉毒梭菌IgA蛋白酶与IgG Fc的嵌合融合蛋白可在IgA肾病小鼠模型中持久清除IgA沉积物

Chimeric Fusion between Clostridium Ramosum IgA Protease and IgG Fc Provides Long-Lasting Clearance of IgA Deposits in Mouse Models of IgA Nephropathy.
PubMed 文献 · J Am Soc Nephrol · 2022-02-16

研究将诺氏梭菌(Clostridium ramosum)IgA蛋白酶AK183与人IgG1 Fc段融合构建Fc-AK183,在小鼠模型中验证其裂解并清除IgA的能力。Fc-AK183在 mice 中展现长达一周的酶活性,可持久清除血IgA并去除肾小球慢性IgA及补体C3沉积,作者认为其有望成为IgA肾病的靶向治疗。

要点

  • Fc-AK183融合蛋白在小鼠体内酶活性可持续一周。
  • Fc-AK183裂解IgA后片段经肾脏滤过有效清除。
  • Fc-AK183可清除肾小球慢性IgA及补体C3沉积。

核心结论

  • 作者构建了IgA蛋白酶与Fc的嵌合融合蛋白,并在小鼠模型中证实其具有持久疗效,有望成为IgA肾病的靶向治疗。

研究设计与样本

  • 研究为实验性研究,以诺氏梭菌(Clostridium ramosum)IgA蛋白酶AK183为模板构建重组生物制剂,将AK183与人IgG1 Fc段融合,并在小鼠模型中测试Fc-AK183对IgA的裂解和清除活性。

主要发现

  • AK183具有自切割活性,可将N端蛋白酶与C端自转运β结构域分离,因此将Fc嫁接到AK183的N端,并在小鼠中证实其酶活性持续一周。
  • Fc-AK183与IgA反应产生的蛋白水解片段通过肾脏滤过从循环中有效清除。
  • 在人IgA注射模型和人源化α1KI转基因模型中,Fc-AK183介导的裂解及随后的肾脏清除共同作用导致血IgA持久消除。
  • Fc-AK183还能去除肾小球中慢性的IgA及相关的补体C3沉积。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IgA nephropathy is a common primary glomerulonephritis caused by mesangial deposition of poly-IgA complexes. The disease follows a variable course of clinical progression, with a high risk of kidney failure. Although no specific therapy is available, enzymatic strategies to clear IgA deposits are being considered for the treatment of rapidly progressive IgA nephropathy. METHODS: We chose an IgA protease of commensal bacterium Clostridium ramosum, termed AK183, as the template for constructing a recombinant biologic. To extend the t1/2 in blood, we fused AK183 to the Fc segment of human IgG1. Activities of this Fc-AK183 fusion protein toward the cleavage and subsequent clearance of IgA were tested in mouse models. RESULTS: First, we discovered an autocleavage activity of AK183 that separates the N-terminal protease from its C-terminal autotransporter β domain. Therefore, we grafted Fc to the N terminus of AK183 and demonstrated its week-long enzymatic activity in mice. In addition, the proteolytic fragments of IgA generated in the reaction with Fc-AK183 were effectively removed from circulation via kidney filtration. The combined actions of Fc-AK183-mediated cleavage and subsequent renal clearance of IgA resulted in a lasting obliteration of blood IgA, as demonstrated in a human IgA-injection model and in a humanized α1KI transgenic model. Fc-AK183 was also able to remove chronic IgA and associated complement C3 deposits in the glomerulus. CONCLUSION: We constructed a chimeric fusion of IgA protease with Fc and demonstrated its long-lasting efficacy as a promising targeted therapy for IgA nephropathy in mouse models.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Xie X, Li J, Liu P, et al. Chimeric Fusion between Clostridium Ramosum IgA Protease and IgG Fc Provides Long-Lasting Clearance of IgA Deposits in Mouse Models of IgA Nephropathy. J Am Soc Nephrol. 2022. PMID: 35172987. doi:10.1681/ASN.2021030372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。